3350 Stock Overview
A biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aadi Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.91 |
| 52 Week High | US$4.82 |
| 52 Week Low | US$1.18 |
| Beta | 0.37 |
| 11 Month Change | 7.91% |
| 3 Month Change | 52.80% |
| 1 Year Change | -54.31% |
| 33 Year Change | -90.73% |
| 5 Year Change | n/a |
| Change since IPO | -90.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3350 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.5% | -0.009% | -1.2% |
| 1Y | -54.3% | -17.6% | 9.0% |
Return vs Industry: 3350 underperformed the German Biotechs industry which returned -17.1% over the past year.
Return vs Market: 3350 underperformed the German Market which returned 13.5% over the past year.
Price Volatility
| 3350 volatility | |
|---|---|
| 3350 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3350 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 3350's weekly volatility has decreased from 11% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 70 | Dave Lennon | aadibio.com |
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience, Inc. Fundamentals Summary
| 3350 fundamental statistics | |
|---|---|
| Market cap | €48.75m |
| Earnings (TTM) | -€58.10m |
| Revenue (TTM) | €23.61m |
2.1x
P/S Ratio-0.9x
P/E RatioIs 3350 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3350 income statement (TTM) | |
|---|---|
| Revenue | US$25.07m |
| Cost of Revenue | US$52.61m |
| Gross Profit | -US$27.54m |
| Other Expenses | US$34.15m |
| Earnings | -US$61.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.50 |
| Gross Margin | -109.86% |
| Net Profit Margin | -246.06% |
| Debt/Equity Ratio | 0% |
How did 3350 perform over the long term?
See historical performance and comparison